Abstract
Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number of pharmacological studies. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of antiinflammatory activity. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of COX inhibitors. The mechanism of their gastric-sparing properties is not completely understood, although it has been demonstrated that leukotrienes significantly contribute to the gastric epithelial injury. Finally, both COX and LOX derivatives (prostanoids and leukotrienes, respectively) are involved in other diseases than inflammation such as cancer proliferation where the use of dual inhibitors could be an interesting approach.
Keywords: cox inhibitors, prostanoids, leukotrienes, eicosanoids, cyclooxygenase, peroxidase, meclofenamic acid, flufenamic acid, mefenamic acid, niflumic acid
Current Medicinal Chemistry
Title: New Trends in Dual 5-LOX / COX Inhibition
Volume: 9 Issue: 9
Author(s): Xavier de Leval, Fabien Julemont, Jacques Delarge, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Keywords: cox inhibitors, prostanoids, leukotrienes, eicosanoids, cyclooxygenase, peroxidase, meclofenamic acid, flufenamic acid, mefenamic acid, niflumic acid
Abstract: Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number of pharmacological studies. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of antiinflammatory activity. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of COX inhibitors. The mechanism of their gastric-sparing properties is not completely understood, although it has been demonstrated that leukotrienes significantly contribute to the gastric epithelial injury. Finally, both COX and LOX derivatives (prostanoids and leukotrienes, respectively) are involved in other diseases than inflammation such as cancer proliferation where the use of dual inhibitors could be an interesting approach.
Export Options
About this article
Cite this article as:
Leval de Xavier, Julemont Fabien, Delarge Jacques, Pirotte Bernard and Dogne Jean-Michel, New Trends in Dual 5-LOX / COX Inhibition, Current Medicinal Chemistry 2002; 9 (9) . https://dx.doi.org/10.2174/0929867024606713
DOI https://dx.doi.org/10.2174/0929867024606713 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Topical Gene Delivery in Mice Using Gemini Surfactant - Lipid Nanoparticles With and Without Tape Electrode Electroporation
Drug Delivery Letters Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Current Alzheimer Research Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Genetic Polymorphisms of Human Sulfate Transporters
Current Pharmacogenomics Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD)
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
Current Medicinal Chemistry Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology TNF and TNF Receptors in TRAPS
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Expressional Analysis and Role of Calcium Regulated Kinases in Abiotic Stress Signaling
Current Genomics Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Reshaping the Protein Folding Pathway by Osmolyte via its Effects on the Folding Intermediates
Current Protein & Peptide Science Progresses of Somatostatin Quantification for Clinical Practice
Current Pharmaceutical Analysis WITHDRAWN: Current Trends in the Detection of Biological Proteins and Immunological Assays using Graphene Quantum Dots
Current Analytical Chemistry